PHARMACY

Drug for hypertension in children launched

BY Alaric DeArment

DENVER — Silvergate Pharmaceuticals has launched a new drug for treating high blood pressure in children, the company said Monday.

The drug maker announced the availability of Epaned (enalapril maleate) powder for oral suspension, for treating hypertension in patients older than 1 month. Enalapril is one of the most commonly prescribed medicines in the United States for high blood pressure. Epaned was approved in August 2013 as a flavored liquid solution to appeal to children and others who have difficulty swallowing enalapril tablets.

"We’re pleased to launch Epaned so quickly after receiving FDA approval," Silvergate president and CEO Frank Segrave said. "Silvergate is happy to take the lead in developing FDA-approved medicines for children, an area of drug development that is often overlooked."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Good Neighbor Pharmacy, KaBOOM! and the Community YMCA design, build dream play space for children

BY Michael Johnsen

RED BANK, N.J. — In less than eight hours, a play space was built at the Community YMCA’s Family Health and Wellness Center with the help of more than 200 volunteers from the Community YMCA, Good Neighbor Pharmacy and non profit KaBOOM!, the companies announced Monday. The new playground — which was made possible by funds donated by Good Neighbor Pharmacy and matched by its parent company, AmerisourceBergen — will serve hundreds of children in the community for years to come.

“The Community YMCA is truly grateful to KaBOOM! and Good Neighbor Pharmacy for their generosity and commitment to ensuring that all children have a safe place to play,” stated the Community YMCA president and CEO Rhonda Anderson. “We thank them and the many hardworking volunteers and local businesses who supported this project. Together, we are making a lasting impact for children in our community.” 

Planning for the playground began at a design day event held on Sept. 3, where local children and community leaders met with organizers from KaBOOM! and Good Neighbor Pharmacy to design their dream playground. The children’s drawings were then used to create the final playground design.

“Good Neighbor Pharmacy is thrilled to have the opportunity to give back to local communities like Red Bank through our partnership with KaBOOM!,” stated AJ Caffentzis, SVP sales and marketing, at AmerisourceBergen. “We are committed to the health and well-being of our customers, employees and communities. Our Good Neighbor Pharmacy members, in particular, remain cornerstones of their respective communities, working to improve patient access and patient health in local neighborhoods across the country. We view our partnership with KaBOOM! as an extension of our commitment to local communities.”

The playground is the first of five that will be built together by KaBOOM! and Good Neighbor Pharmacy, the companies noted.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

UCB seeks approval for Vimpat as stand-alone therapy in adults

BY Alaric DeArment

ATLANTA — Drug maker UCB is seeking approval for one of its drugs as a stand-alone therapy for epilepsy.

The company said Monday that the Food and Drug Administration had accepted its regulatory approval application for Vimpat (lacosamide) for adult epilepsy patients with partial-onset seizures. The drug is already approved as an add-on therapy for partial-onset seizures in patients aged 17 and older.

"UCB has a strong heritage in epilepsy," UCB chief medical officer and EVP Iris Loew-Friedrich said. "The US filing for lacosamide in monotherapy is another step forward for people living with epilepsy."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?